Navigation Links
Volcano Corporation Provides Additional Guidance For 2013
Date:2/21/2013

and technical issues; market conditions and  other risks inherent to medical and/or telecom device development and commercialization. These and additional risks and uncertainties are more fully described in Volcano's filings made with the Securities and Exchange Commission, including our prospectus supplement on Form 424b2,  and other filings made with the Securities and Exchange Commission. Additional information will also be set forth in our Form 10-K that will be filed for the year ended December 31, 2012, which should be read in conjunction with these financial results. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Volcano disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.VOLCANO CORPORATIONRECONCILIATION OF GAAP TO NON-GAAP EPS GUIDANCE(in thousands, except per share data)(Unaudited)2013Guidance RangeFromTo GAAP net loss per share—basic 

$  (0.23)$  (0.19) GAAP net loss per share—diluted 

$  (0.22)$  (0.19)  Acquisition related items 

0.050.05  Amortization of intangibles 

0.040.04  Non-cash interest expense 

0.210.21 Non-GAAP net income per share—diluted 

$
.08$
.11 Weighted average shares outstanding—basic 

54,40054,400 Weighted average shares outstanding—diluted 

56,20056,200Note: Effective tax rate of 38% applied to non-GAAP adjustments
'/>"/>

SOURCE Volcano Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Volcano Announces Record Fourth Quarter Revenues
2. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
3. Volcano Corporation Prices Offering Of $400 Million 1.75% Convertible Senior Notes Due 2017
4. Volcano Corporation To Offer $350 Million Convertible Senior Notes Due 2017
5. Volcano Corporation Signs Agreement to Acquire Sync-Rx Ltd.
6. Volcano Corporation Presentation At Piper Jaffray Conference To Be Webcast
7. Fish & Richardson Prevails in Patent Infringement Trial for Volcano Corporation
8. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
9. Volcano Announces Previous St. Jude Medical Products Infringe Volcano Patent and Jury Verdicts in Patent Trials with St. Jude Medical
10. Volcano Corporation Presentation At Stifel Nicolaus Conference To Be Webcast
11. FAME 2 Published in the New England Journal of Medicine, Volcano participates in the $84M NIH-Sponsored ISCHEMIA Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 25, 2014  goBalto, Inc., the ... been recognized as a winner of Red Herring,s ... Global Top 100 North America award in 2013, marking ... technology landscape. Red Herring,s Top 100 Global ... promising new companies and entrepreneurs. Red Herring editors were ...
(Date:11/26/2014)... 25, 2014   Heska Corporation (NASDAQ: ... a provider of advanced veterinary diagnostic and other specialty ... Executive Chair, will attend The Benchmark Company, LLC,s Micro Cap ... will be held at The Palmer House Hilton, 17 E. ... a.m. to 2:30 p.m. Please email hska@haydenir.com or ...
(Date:11/26/2014)... and LONDON , Nov. 25, 2014 /PRNewswire/ ... AZN ) today announced that AMAGINE-2 TM , ... brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, ... (ustekinumab) and placebo at week 12. Brodalumab 210 mg ... were each shown to be superior to Stelara on the ...
Breaking Medicine Technology:goBalto Selected as a 2014 Red Herring Top 100 Global Company 2goBalto Selected as a 2014 Red Herring Top 100 Global Company 3Heska to Attend Benchmark Micro Cap Discovery Conference 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
... Safety and Efficacy Data Presented at 1st IASLC-ESMO European Lung ... ... 23 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company ... 2,clinical trial of picoplatin confirming previously announced interim,results showing a survival ...
... 23 Archus Orthopedics, Inc.,announced today that it ... TFAS-C(TM) system, the newest addition to the company,s ... which degenerative changes in,the facet joints result in ... legs. Traditionally, patients with moderate to,severe spinal stenosis ...
Cached Medicine Technology:Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit 2Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit 3Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit 4First Human Implant of New Archus Orthopedics Facet Replacement System 2
(Date:11/27/2014)... In a world enveloped in ... has lessened, and due to the intrusion of ... sleep has eroded. According to Web MD, one ... (Reference: http://www.webmd.com/sleep-disorders/features/sleep-deprivation-workplace ). This remarkably high number ... incalculable amount, leading not only to dissatisfied employers, ...
(Date:11/27/2014)... 2014 An inventor from Buffalo, N.Y., ... of life, and she wants to lessen its impact. ... I decided that there needed to be a way ... Easy to use and producible in design variations, the ... private areas throughout the day. It avoids bad odors, ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 Nearly ... been filed in a consolidated litigation now underway ... , Documents recently updated in the Philadelphia ... in the state proceeding, all of which involve ... and other psychiatric conditions. Many of the cases ...
(Date:11/27/2014)... -- Most babies and young children don,t need medicines ... Drug Administration says. Over-the-counter (OTC) cold and cough ... 2 because they could cause serious and potentially deadly ... about three colds a year, but children get them ... want to give them pain relievers, decongestants and other ...
(Date:11/27/2014)... meals can pose a challenge for people who have ... Many traditional Thanksgiving dishes -- such as turkey, corn, ... "when it comes to pies, stuffing, gravy, etc., gluten-free ... director of the Gluten and Allergic Digestive Disorders program ... said in a center news release. "For those ...
Breaking Medicine News(10 mins):Health News:Research Shows Surprising Number of US Workers Affected by Lack of Sleep 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:Expert Shares Gluten-Free Thanksgiving Tips 2
... ptient with a turbocharger for the heart called C-Pulse.// ... moderate heart problems, who are still not ill enough to ... These patients may be those who may feel extreme tiredness, ... help from medications. ,The new device is a balloon ...
... may have less tolerance to alcohol intakes than men, suggests ... 2005//. ,Researchers of University of Pittsburgh School of Medicine ... things to women than their male counterparts. Women may be ... men even if they have the same amount of the ...
... colonoscopy may be the favorable method to screen women// ... cancer, flexible sigmoidoscopy is used to detect colorectal neoplasias, ... dysplasia, or cancer. Researchers had used colonoscopy to detect ... women who were referred for colon-cancer screenings. ,Of the ...
... that extracts of the grapefruit seeds contain antioxidants ... a fruit, grapefruit had been associated with acidity ... and helpful ingredients that have healing properties. Researchers ... and presented their study findings at the Digestive ...
... research presented at Digestive Disease Week 2005, antidepressants ... depression, also known as unipolar depression, is often ... inhibitors (SSRIs) by physicians. , ,Previous research ... (NSAID) can cause increased bleeding and hemorrhage in ...
... Baptist Medical Center, US, have found that low doses ... and thus limits the side effects of the therapy ... chemotherapy given to children suffering from Acute Lymphblastic Leukemia ... cancer were administered very limited dosage of chemotherapy and ...
Cached Medicine News:
... highest g-force ever. But optimal productivity in ... MAX combines maximum force, capacity, and ease ... worlds apart from any other system. With ... efficiency, Optima takes productivity to the MAX. ...
... ultracentrifuge is designed to play a ... if research involves proteomics, cytomics or ... computer, enhanced firmware, powerful Optima eXPert ... Optima L-XP delivers superior functionality, optimized ...
... The Dimension Xpand integrated chemistry ... compact footprint to the smaller laboratory. ... The Dimension Xpand integrated chemistry system ... tailored for the low-volume environment, in ...
The Express Plus clinical chemistry analyzer is a fully automated walk away system designed for maximum productivity, convenience and reliability....
Medicine Products: